Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“PTEN loss is associated with worse outcomes in prostate cancer. Now there’s a way to act on it in the hormone-sensitive setting.
CAPItello-281: capivasertib + abiraterone improved rPFS in PTEN-deficient mHSPC, 33.2 vs 25.7 mo, HR 0.81. FDA approved this month, PTEN by IHC.
The AKT inhibitor adds hyperglycemia, diarrhea, and rash, including grade 3 rash.
Plan for it: check glucose at baseline and on treatment with metformin ready, antihistamine prophylaxis for rash, loperamide early for diarrhea (onset around day 9).
Why this matters for your practice: The supportive care and counseling need to be set up early before the first dose.
What are you recommendations for handling glucose and skin monitoring for these patients?
CAPItello-281 full results.”
Title: Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
Authors: K. Fizazi, N.W. Clarke, M. De Santis, H. Uemura, A.P. Fay, N. Karadurmus, M. Kwiatkowski, C. Alvarez-Fernandez, S. Jiang, M. Sotelo, D. Parslow, N. Oliveira, T.G. Kwon, D. Ye, S. Boudewijns, P. Danchaivijitr, C. Rooney, C. Gresty, M. Yeste-Velasco, J. Logan, D.J. George
Other articles featuring Katy Beckermann on OncoDaily.
